Medicine and Dentistry
Hyaluronidase
100%
Neoplasm
66%
Oncolytic Virus
66%
Osteosarcoma
66%
Therapeutic Procedure
66%
Diseases
33%
Gene Therapy
33%
Promoter Region
33%
Nodular Melanoma
33%
Biological Product
33%
Tumor Progression
33%
Cell Therapy
33%
Toxicity
33%
Cohort Effect
33%
Cytotoxicity
33%
Binding Site
33%
Adverse Event
33%
Malignant Neoplasm
33%
Combination Therapy
33%
Adenoma
33%
Xenograft
33%
Hepatocellular Carcinoma
33%
Canine Adenovirus 2
33%
Integrin
33%
Disseminated Intravascular Coagulation
33%
Human Adenovirus C
33%
Oncolytic Adenovirus
33%
Tumor Cell Destruction
33%
Protein Splicing
33%
Fibrosarcoma
33%
Survival
33%
Selectivity
33%
Pharmacology, Toxicology and Pharmaceutical Science
Hyaluronidase
100%
Neoplasm
66%
Osteosarcoma
66%
Oncolytic Virus
66%
Diseases
33%
Toxicity
33%
Biological Product
33%
Binding Site
33%
Adverse Event
33%
Cytotoxicity
33%
Epidemiology
33%
Tumor Growth
33%
Fibrosarcoma
33%
Liver Cell Carcinoma
33%
Melanoma
33%
Disseminated Intravascular Clotting
33%
Preclinical Study
33%
Human Adenovirus C
33%
Oncolytic Adenovirus
33%
Malignant Neoplasm
33%
Canine Adenovirus 2
33%
Adenoma
33%
Animal
33%
Virus
33%
Mouse
33%
Survival
33%
Dog
33%
Biochemistry, Genetics and Molecular Biology
Hyaluronidase
100%
Promoter Region
33%
Nested Gene
33%
Preclinical Study
33%
Binding Site
33%
Cytotoxicity
33%
Dog
33%
Disseminated Intravascular Coagulation
33%
Growth
33%
Human Adenovirus C
33%
Canine Adenovirus 2
33%
Tumor Cell Destruction
33%
Protein Splicing
33%
E2F
33%
Animal Models
33%
Virus
33%
Mouse
33%
Survival
33%
Genetics
33%
Integrin
33%
Immunology and Microbiology
Oncolytic Virus
66%
Biological Product
33%
Promoter Region
33%
Cytotoxicity
33%
Preclinical Study
33%
Mouse
33%
Binding Site
33%
Growth
33%
Canine Adenovirus 2
33%
Integrin
33%
Xenograft
33%
Human Adenovirus C
33%
Protein Splicing
33%
Oncolytic Adenovirus
33%
Tumor Cell Destruction
33%
Dog
33%
Gene
33%
Cells
33%
Survival
33%
Veterinary Science and Veterinary Medicine
Osteosarcoma
66%
Disseminated Intravascular Coagulation
33%
Fibrosarcoma
33%
Binding Site
33%
E2F
33%
Veterinary Oncology
33%